首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688197 首药控股

已收盘 08-23 15:00:00

{"stockData":{"symbol":"688197","market":"SH","secType":"STK","nameCN":"首药控股","latestPrice":33.9,"timestamp":1724396400000,"preClose":33.99,"halted":0,"volume":379818,"delay":0,"floatShares":55766200,"shares":149000000,"eps":-1.2897,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.09,"latestTime":"08-23 15:00:00","open":33.82,"high":33.93,"low":33.08,"amount":12720600,"amplitude":0.025,"askPrice":33.9,"askSize":12,"bidPrice":33.85,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-1.2897,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":33.99,"symbolType":"stock_kcb","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":37.39,"lowLimit":30.59,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":148719343,"pbRate":5.21,"roa":"--","roe":"--","epsLYR":-1.25,"committee":-0.02,"marketValue":5042000000,"floatMarketCap":1890000000,"peRate":-26.285182,"changeRate":-0.0026,"turnoverRate":0.0068,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-08-26。","afterMarket":{"amount":0,"volume":0,"close":33.9,"buyVolume":0,"sellVolume":0,"time":1724398437153,"indexStatus":"已收盘 08-23 15:30:00","preClose":33.99}},"requestUrl":"/m/hq/s/688197/tweets","defaultTab":"tweets","newsList":[{"id":"2462644724","title":"首药控股(688197.SH)：SY-7166片单药用于治疗多发性骨髓瘤的临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2462644724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462644724?lang=zh_cn&edition=full","pubTime":"2024-08-25 15:52","pubTimestamp":1724572358,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)公告，公司于近日收到国家药品监督管理局(“国家药监局”)核准签发的《药物临床试验批准通知书》，公司SY-7166片单药用于治疗多发性骨髓瘤的临床试验申请获得批准。据悉，多发性骨髓瘤(Multiple Myeloma，MM)是一种克隆浆细胞异常增殖的恶性疾病，其特征为骨髓浆细胞异常增生伴有单克隆免疫球蛋白或轻链(M蛋白)过度生成。目前，我国多发性骨髓瘤位居血液系统恶性肿瘤第2位，2020年新增多发性骨髓瘤病例21,116例，死亡病例16,182例，发病率以每年2.5%的速率上升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1170118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4077","03347","BK4503","SY","BK0239","BK1141","BK1583","BK1576","BK4563","688197"],"gpt_icon":0},{"id":"2462082644","title":"首药控股最新公告：SY-7166片单药用于治疗多发性骨髓瘤的临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2462082644","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462082644?lang=zh_cn&edition=full","pubTime":"2024-08-25 15:51","pubTimestamp":1724572272,"startTime":"0","endTime":"0","summary":"首药控股公告称，公司近日收到国家药监局核准签发的《药物临床试验批准通知书》，公司SY-7166片单药用于治疗多发性骨髓瘤的临床试验申请获得批准。SY-7166是一款高活性、高选择性的免疫蛋白酶体抑制剂，拥有良好的临床前抗肿瘤活性和安全性。然而，由于创新药研发周期长、环节多，存在诸多不确定因素，公司无法保证临床试验数据能够预测候选药物的最终临床结果。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082500002101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0239","BK1583","BK1576","688197","03347"],"gpt_icon":0},{"id":"2462644101","title":"首药控股(688197.SH)发布半年度业绩 净亏损1.03亿元 同比扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2462644101","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462644101?lang=zh_cn&edition=full","pubTime":"2024-08-25 15:44","pubTimestamp":1724571887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)披露2024年半年度报告，该公司报告期实现营业收入380万元，同比下降24.00%。归属于上市公司股东的净亏损1.03亿元，归属于上市公司股东的扣除非经常性损益的净亏损1.10亿元，亏损同比扩大。报告期内，该公司通过巩固综合研发能力，优化临床开发策略，认真、高效做好选择性RET抑制剂SY-5007、第三代ALK抑制剂SY-3505的关键性Ⅱ/Ⅲ期临床试验、SY-707确证性Ⅲ期试验的各项关键核心工作。报告期内，合理、有序投入研发资金1.07亿元，同比增长5.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1170111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2459516694","title":"首药控股（688197）8月14日主力资金净卖出7.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459516694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459516694?lang=zh_cn&edition=full","pubTime":"2024-08-15 08:23","pubTimestamp":1723681398,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月14日收盘，首药控股报收于35.2元，下跌2.52%，换手率0.41%，成交量2293.0手，成交额807.46万元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入57.9万元，融资偿还44.15万元，融资净买入13.75万元。首药控股主营业务：肿瘤和糖尿病药物的研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081500012887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2457918140","title":"8月6日首药控股-U涨8.38%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2457918140","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457918140?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:11","pubTimestamp":1722931909,"startTime":"0","endTime":"0","summary":"证券之星消息，8月6日首药控股-U涨8.38%，收盘报37.64元，换手率2.02%，成交量1.13万手，成交额4186.18万元。该股为医药、创新药概念热股。重仓首药控股-U的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为22.77亿元，最新净值0.9358，较上一交易日下跌0.47%，近一年下跌8.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600030718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","09939","159938","688197","BK1515","BK0239"],"gpt_icon":0},{"id":"2457767654","title":"首药控股-U8月2日获融资净买入238万元 环比增加28020.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457767654","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457767654?lang=zh_cn&edition=full","pubTime":"2024-08-05 10:00","pubTimestamp":1722823217,"startTime":"0","endTime":"0","summary":"8月2日，首药控股-U获融资净买入238万元，环比上一交易日增加28020.23%。其中，融资买入299万元，融资偿还60万元。融券方面，融券卖出0.00万股，当前融券余量为0.68万股。A股市场共有1599股获融资净买入，首药控股-U净买入额排名第248。股市有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805100135957d8a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805100135957d8a9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2456424033","title":"首药控股-U08月02日主力资金流入164万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2456424033","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456424033?lang=zh_cn&edition=full","pubTime":"2024-08-02 15:18","pubTimestamp":1722583121,"startTime":"0","endTime":"0","summary":"08月02日, 首药控股-U股价涨2.61%，报收35.00元，成交金额2211万元，换手率1.13%，振幅6.74%，量比1.24。首药控股-U今日主力资金净流入164万元，连续3日净流入，上一交易日主力净流入45万元，今日环比增加264.44%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为47.83%，平均涨幅为3.35%。该股近5个交易日上涨1.89%，主力资金累计净流入268万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1603万元，其中净流入天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080215293795770404&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080215293795770404&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2456307490","title":"首药控股（688197）8月1日主力资金净买入43.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456307490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456307490?lang=zh_cn&edition=full","pubTime":"2024-08-02 08:20","pubTimestamp":1722558015,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月1日收盘，首药控股报收于34.11元，下跌3.01%，换手率0.9%，成交量5025.0手，成交额1735.46万元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入57.26万元，融资偿还56.41万元，融资净买入0.85万元，连续3日净买入累计143.62万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080200012491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2455081928","title":"09:25 三大指数集体低开，沪指低开0.06%，深成指低开0.26%，创业板指低开0.48% 09:34 智能网约车概念股继续走强，大众公用5连板，锦江在线3连板，龙江交通、海汽集团涨停，大众交通涨超6% 09:48 券商股异动拉升，锦龙股份8天5板，华鑫股份冲击涨停，国盛金控、天风证券、东北证券、华创云信等纷纷走强 09:51 深成指、创业板指双双涨逾1%，沪指涨0.","url":"https://stock-news.laohu8.com/highlight/detail?id=2455081928","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455081928?lang=zh_cn&edition=full","pubTime":"2024-07-31 11:50","pubTimestamp":1722397814,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["688017","159982","159891","09939","300503","399001","BK0264","600686","001379","000686","300147","BK0234","399006","161027","603662","002829","06978","600611","603069","301368","159992","600650","BK0070","300024","600621","002896","002670","688177","BK0053","BK0276","01981","688160","002262","000712","688192","159938","688197","688202","01635","600155","002232","159526","601188","BK0010","601162","399300","600635","BK0252","BK0060"],"gpt_icon":0},{"id":"2455949811","title":"创新药板块震荡反弹，香雪制药涨超15%，百奥泰、恩华药业、首药控股、迪哲医药、美迪西等多股涨逾5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2455949811","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455949811?lang=zh_cn&edition=full","pubTime":"2024-07-31 10:14","pubTimestamp":1722392098,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["002262","BK0060","688197","300147","688202","BK1574","688177","06978","BK0216","BK0070","688192","BK0239","BK1161","BK0188","159992","BK0028"],"gpt_icon":0},{"id":"2455994577","title":"首药控股-U大幅上涨 创新药临床试验审评审批改革工作将开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2455994577","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455994577?lang=zh_cn&edition=full","pubTime":"2024-07-31 09:59","pubTimestamp":1722391180,"startTime":"0","endTime":"0","summary":"消息解读7月30日，国家药监局党组书记、局长李利主持召开会议，研究部署创新药临床试验审评审批改革工作，审议通过《优化创新药临床试验审评审批试点工作方案》。《优化创新药临床试验审评审批试点工作方案》将于近日发布。资金动向截止发稿，首药控股-U获得主力净流出22万元。主营业务及业绩首药控股-U公司主营业务为小分子抗肿瘤药物研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731100014af94f772&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731100014af94f772&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688197","BK0239"],"gpt_icon":0},{"id":"2455144229","title":"首药控股（688197）7月30日主力资金净卖出13.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455144229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455144229?lang=zh_cn&edition=full","pubTime":"2024-07-31 08:25","pubTimestamp":1722385535,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月30日收盘，首药控股报收于33.25元，下跌1.22%，换手率0.52%，成交量2887.0手，成交额958.72万元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入49.3万元，融资偿还23.82万元，融资净买入25.48万元，连续3日净买入累计105.22万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100014760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2454435085","title":"首药控股-U大跌5.03% 1家券商给予买入建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2454435085","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454435085?lang=zh_cn&edition=full","pubTime":"2024-07-26 11:13","pubTimestamp":1721963595,"startTime":"0","endTime":"0","summary":"07月26日，首药控股-U股价大幅下跌，截至11点13分，首药控股-U下跌5.03%，报33.07元/股，创近5月新低，成交1359万元，换手率0.72%，振幅5.66%。资金动向截止发稿，首药控股-U获得主力净流入2万元。北向资金方面，首药控股-U07月25日获得北向资金增持0.04万股，截至07月25日，北向资金当前共持有首药控股-U5.07万股，市值167万元，持股占流通股比为0.09%。主营业务及业绩首药控股-U公司主营业务为小分子抗肿瘤药物研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726111321af943c5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726111321af943c5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2454548163","title":"A股创新药概念股震荡走低，特宝生物短线跳水跌超5%，迈威生物、首药控股等跌超3%，华润三九、诺思格、百花医药等跟跌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454548163","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454548163?lang=zh_cn&edition=full","pubTime":"2024-07-26 10:21","pubTimestamp":1721960468,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0010","688278","BK0239","BK0183","BK0196","BK0028","688197","688062","BK0216","000999","399300","159992","600721","BK0175","BK0188","BK1161","BK0185","159982","BK0012","BK0060","06978","301333","BK1574","BK0102"],"gpt_icon":0},{"id":"2454935101","title":"【创新药概念股震荡走低，特宝生物短线跳水跌超5%】 创新药概念股震荡走低，特宝生物短线跳水跌超5%，迈威生物、首药控股等跌超3%，华润三九、诺思格、百花医药等跟跌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454935101","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454935101?lang=zh_cn&edition=full","pubTime":"2024-07-26 10:20","pubTimestamp":1721960453,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0216","BK1161","BK0188","BK0012","600721","BK1574","BK0196","BK0175","BK0239","BK0185","BK0010","688278","BK0102","BK0060","688197","BK0028","159992","301333","000999","06978","688062","BK0183"],"gpt_icon":0},{"id":"2454370753","title":"首药控股（688197）7月25日主力资金净卖出11.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454370753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454370753?lang=zh_cn&edition=full","pubTime":"2024-07-26 08:25","pubTimestamp":1721953551,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月25日收盘，首药控股报收于34.82元，下跌1.33%，换手率0.49%，成交量2714.0手，成交额957.73万元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入69.6万元，融资偿还56.63万元，融资净买入12.97万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072600012778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2453042296","title":"首药控股-U大跌5.03% 北向资金减持3.44万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453042296","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453042296?lang=zh_cn&edition=full","pubTime":"2024-07-24 13:14","pubTimestamp":1721798092,"startTime":"0","endTime":"0","summary":"07月24日，首药控股-U股价大幅下跌，截至13点14分，首药控股-U下跌5.03%，报35.33元/股，成交1205万元，换手率0.60%，振幅6.72%。资金动向截止发稿，首药控股-U获得主力净流出73万元。北向资金方面，首药控股-U07月23日获得北向资金减持3.44万股，截至07月23日，北向资金当前共持有首药控股-U5.93万股，市值209万元，持股占流通股比为0.10%。主营业务及业绩首药控股-U公司主营业务为小分子抗肿瘤药物研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724131501af93ceaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724131501af93ceaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2453707665","title":"7月23日首药控股-U跌6.77%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453707665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453707665?lang=zh_cn&edition=full","pubTime":"2024-07-23 16:15","pubTimestamp":1721722517,"startTime":"0","endTime":"0","summary":"证券之星消息，7月23日首药控股-U跌6.77%，收盘报37.2元，换手率0.76%，成交量4263.0手，成交额1620.08万元。该股为医药、创新药概念热股。重仓首药控股-U的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为22.77亿元，最新净值0.9715，较上一交易日上涨0.49%，近一年下跌7.12%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300029527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","159938","09939","BK1515","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"2453940720","title":"首药控股-U大跌5.54% 北向资金增持1.10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453940720","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453940720?lang=zh_cn&edition=full","pubTime":"2024-07-23 10:35","pubTimestamp":1721702158,"startTime":"0","endTime":"0","summary":"07月23日，首药控股-U股价大幅下跌，截至10点35分，首药控股-U下跌5.54%，报37.69元/股，成交600万元，换手率0.28%。资金动向截止发稿，首药控股-U获得主力净流入41万元。北向资金方面，首药控股-U07月22日获得北向资金增持1.10万股，截至07月22日，北向资金当前共持有首药控股-U9.37万股，市值353万元，持股占流通股比为0.16%。主营业务及业绩首药控股-U公司主营业务为小分子抗肿瘤药物研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723103607af9389a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723103607af9389a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2452175454","title":"首药控股-U大幅上涨 获北向资金减持1.51万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452175454","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452175454?lang=zh_cn&edition=full","pubTime":"2024-07-19 14:53","pubTimestamp":1721372032,"startTime":"0","endTime":"0","summary":"资金动向截止发稿，首药控股-U获得主力净流入135万元，其中超大单流入392万元，大单流出257万元。北向资金方面，首药控股-U07月18日获得北向资金减持1.51万股，截至07月18日，北向资金当前共持有首药控股-U5.10万股，市值211万元，持股占流通股比为0.09%。主营业务及业绩首药控股-U公司主营业务为小分子抗肿瘤药物研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719145402af931b38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719145402af931b38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-23","address":"北京市大兴区北京经济技术开发区荣华中路10号1幢A座22层2205","stockEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":-0.0394},{"period":"3month","weight":-0.2483},{"period":"6month","weight":-0.1814},{"period":"1year","weight":-0.2361},{"period":"ytd","weight":-0.3858}],"companyName":"首药控股(北京)股份有限公司","boardCode":"AI0027","perCapita":"18362股","boardName":"医药制造业","registeredCapital":"14871万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":"　　首药控股(北京)股份有限公司是一家处于临床研究阶段的小分子创新药企业，研发管线涵盖了非小细胞肺癌、淋巴瘤、肝细胞癌、胰腺癌、甲状腺癌、卵巢癌、白血病等重点肿瘤适应症以及II型糖尿病等其他重要疾病领域。公司主要产品有SY-707(CT-707，Conteltinib)、SY-3505（CT-3505）、SY-1530(CT-1530)、SY-4798,SY-5007、SY-4835。公司被国家科技部认定为国家级“企业创新药物孵化基地”和“G蛋白偶联受体关键技术平台”，被北京市人民政府认定为“中关村生物产业创新基地”，被北京市科学技术委员会认定为“北京市G20创新引领企业”,“北京市肿瘤与糖尿病小分子靶向新药工程技术研究中心”,“北京市科技研究开发机构”。","serverTime":1724576747409,"listedPrice":39.9,"stockholders":"3037人(较上一季度减少15.07%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"首药控股,688197,首药控股股票,首药控股股票老虎,首药控股股票老虎国际,首药控股行情,首药控股股票行情,首药控股股价,首药控股股市,首药控股股票价格,首药控股股票交易,首药控股股票购买,首药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}